ISR NEWS Writeup: ENJOY!!
This article is under the US TRADE VOICE!!
IsoRay, Inc. (NYSEMKT:ISR)’S Cesium-131 – Single Solution Against Cancer
Posted In Healthcare - By Grant Murphy On Friday, April 4th, 2014 With 0 Comments
Dallas, Texas 04/04/2014 (ustradevoice) – IsoRay, Inc. (NYSEMKT:ISR) is the innovator of Cesium-131 and expects to become a ground-breaking treatment method for cancer patients. The medical community has accepted the products due to its positive study results. The Company aims to increase the awareness across medical community over Cesium-131 brachytherapy through American Brachytherapy Society Convention.
Cesium-131
Cesium-131 brachytherapy, a radiation procedure, is used as an early stage treatment against solid cancers. The product allows physicians to place a specified dose of radiation in cancer specific area so that it minimizes the damage to occur in surrounding tissues. The technology has a superior advantage – shorter half-life, effective at higher dose, limited recurrence of the tumor and no side effects compared to other alternative therapies.
Advantage
Cancer is one of the deadly diseases that can occur throughout the body. Though different treatment methods are available, however, increasing side effects allows patients and physicians to think twice before going for any treatment. So, the medical society is looking for a solution that will provide the desired outcome with minimal side effects.
IsoRay, Inc. (NYSEMKT:ISR) intends to provide one solution for cancer through its Cesium-131 brachytherapy. The U.S. FDA also approved Cesium-131 to use against prostate, brain, head, neck, gynecological, colon and lung cancer due to better efficiency compared to other radiation therapies. The product also holds CE mark for its international sales.
The Company also focuses on developing different delivery methods and implantable devices to treat a variety of cancers. Now, IsoRay launched the GliaSite Radiation Therapy System (RTS), an implantable device to treat brain cancer.
Conclusion
Positive study results against different solid cancers and local applications of radiation seed will improve the treatment method. Cesium-131 brachytherapy will consider as future standard treatment against all cancer with increasing acceptance across medical fraternity. The increasing demand will improve IsoRay, Inc. (NYSEMKT:ISR)’s growth potential n foreseeable years.
Tags: IsoRay Inc. (NYSEMKT:ISR), NYSEMKT:ISR
About the Author
Grant Murphy - Grant Murphy graduated from Florida State University with Master in Finance. His experience on WallStreet is depicted by the dept in his writing.
Found this nice news article under the US TRADE VOICE from Wall Street Grant Murphy!
Just another Confirmation of this GREAT LIFE SAVING PRODUCT to help people with cancer.
GO ISORAY!!
Respectfully,
Tim
AI
